Login to Your Account

Gadeta's $7.8M round to advance gamma delta T-cell immunotherapy

By Nuala Moran
Staff Writer

Tuesday, March 29, 2016

LONDON – Dutch start-up Gadeta BV has raised €7 million (US$7.8 million) in a series A, to fund initial clinical development of a novel approach to T-cell immunotherapy that has the potential to target solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription